The gains (losses) included in earnings resulting from the sale or disposal of tangible assets. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_GainLossOnDispositionOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Acquisitions, Divestitures, Research Collaborations and License Agreements - Textual (Detail) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011 USD ($)	Dec. 31, 2012 Endocyte [Member] USD ($)	Dec. 31, 2012 AiCuris [Member] USD ($)	Dec. 31, 2012 AiCuris [Member] EUR (€)	May 16, 2011 Inspire Pharmaceuticals [Member] USD ($)
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]
Upfront payment related to licensing agreement		$ 120	$ 140	€ 110
Potential future milestone payments		880.0		332.5
Purchase price for acquisition					420
Amount of cash paid per share for acquisition					$ 5.00
Gain on sale of manufacturing facilities and related assets	$ 127